Clinical trial
Liposomal Doxorubicin Compared With Observation or Cyclophosphamide and…
NCT00296010 · ETOP IBCSG Partners Foundation, Other · Terminated
Key facts
| NCT number | NCT00296010 |
|---|---|
| Title | Liposomal Doxorubicin Compared With Observation or Cyclophosphamide and Methotrexate in Treating Older Women Who Have Undergone Surgery for Breast Cancer |
| Official title | Phase III Trial Evaluating the Role of Adjuvant Pegylated Liposomal Doxorubicin (PLD, Caelyx, Doxil) for Women (Age 66 Years or Older) With Endocrine Nonresponsive Breast Cancer Who Are Not Suitable for Being Offered a " Standard Chemotherapy Regimen" |
| Acronym | CASA |
| Lead sponsor | ETOP IBCSG Partners Foundation, Other |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug, Procedure, Radiation |
| Interventions | cyclophosphamide, methotrexate, pegylated liposomal doxorubicin hydrochloride, adjuvant therapy, radiation therapy |
| Enrollment | 77 |
| Start date | Aug 1, 2005 |
| Primary completion | Dec 1, 2011 |
| Completion | Dec 1, 2011 |
| First posted | Feb 24, 2006 |
| Last update posted | Feb 23, 2021 |
| Countries | Australia, Belgium, Hungary, Italy, New Zealand, Romania, Slovenia, Sweden, Switzerland |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: